Related Experiment Video

Updated: Oct 4, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Practical approaches to treating patients with acute decompensated heart failure

A S Maisel1

  • 1Division of Cardiology 111-A, Department of Medicine, San Diego VA Healthcare System, 3350 La Jolla Village Dr, San Diego, CA 92161, USA.

Journal of Cardiac Failure
|October 18, 2001
PubMed

Insights

A simple blood test using B-type natriuretic peptide (BNP) can aid in diagnosing and managing congestive heart failure. Serial testing of BNP in urgent care and hospitals can improve patient outcomes and reduce healthcare costs.

Area of Science:

  • Cardiology
  • Biochemistry
  • Medical Diagnostics

Background:

  • Congestive heart failure (CHF) diagnosis and management present significant healthcare costs.
  • A simple, non-invasive diagnostic tool for CHF is highly desirable.
  • B-type natriuretic peptide (BNP) is a cardiac hormone linked to ventricular pressure and CHF severity.

Purpose of the Study:

  • To evaluate the utility of B-type natriuretic peptide (BNP) testing in diagnosing and managing congestive heart failure.
  • To explore the role of BNP in various clinical settings, including urgent care, inpatient, and outpatient settings.

Main Methods:

  • Review of existing data on BNP levels in patients with suspected or confirmed heart failure.
  • Analysis of BNP's correlation with clinical parameters like dyspnea and left ventricular function.
  • Assessment of BNP's impact on diagnostic strategies and treatment decisions.

Main Results:

  • Serial point-of-care BNP testing is beneficial for patients with dyspnea in urgent care.
  • Low BNP levels effectively rule out left ventricular dysfunction, potentially reducing the need for echocardiography.
  • BNP aids in managing decompensated heart failure, potentially obviating invasive monitoring and tailoring treatment.

Conclusions:

  • BNP serves as a valuable biomarker for diagnosing and managing congestive heart failure across different clinical scenarios.
  • BNP testing can optimize patient care, reduce healthcare costs, and improve treatment titration in both acute and chronic heart failure management.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...